Amorphous solid dispersion formulation
View Patent ↗The present disclosure provides an amorphous solid dispersion containing a Cap-dependent endonuclease inhibitor or a pharmaceutically acceptable salt thereof for oral administration, wherein the Cap-dependent endonuclease inhibitor or a pharmaceutically acceptable salt thereof is dispersed in a matrix formed from the pharmaceutically acceptable polymer. Further disclosed are methods for preparing a above amorphous solid dispersion and a use thereof for treating virus infection and a pharmaceutical composition containing same.
1. An amorphous solid dispersion comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable polymer;
wherein
G is hydrogen or —C(R 2 R 2 ′) —O—C═O)—R 3 , in which each of R 2 and R 2 ′independently is hydrogen or C 1-4 alkyl; R 3 is C 1-4 alkyl;
R 1 is halogen, deuterium, or C 1-4 alkyl;
m is an integer of 1 to 9; and
the star (*) indicates a chiral center:,
wherein the pharmaceutically acceptable polymer is polyvinylpyrrolidone/vinyl acetate copolymer, polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, methacrylic acid and methyl methacrylate copolymer, hydroxypropyl cellulose (HPC), hydroxypropyl methyl cellulose acetate succinate (HPMCAS), hydroxypropyl methyl cellulose phthalate (HPMCP), Polyethylene glycol (PEG), or Kollidon SR; and
wherein the weight ratio of the compound of Formula (I) or a pharmaceutically acceptable salt thereof to the pharmaceutically acceptable polymer is in a range between about 1:1 to about 1:5.
2. The amorphous solid dispersion according to claim 1 , wherein the pharmaceutically acceptable polymer is polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, hydroxypropyl cellulose (HPC), or hydroxypropyl methyl cellulose acetate succinate (HPMCAS).
3. The amorphous solid dispersion according to claim 1 , wherein the pharmaceutically acceptable polymer is polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, HPC-SSL, HPMCAS-MG, or HPMCAS-HG.
4. The amorphous solid dispersion according to claim 1 , wherein the cyclic group in Formula (I) represented by the formula:
is a cyclic group represented by any one of the following structures:
5. The amorphous solid dispersion according to claim 4 , wherein the compound is [1-((11S)-7,8-difluoro(6H,11H-dibenzo[c,f]thiepin-11-yl))-4,6-dioxospiro[1,2,3,9-tetrahydropyridino[1,2-e[pyridazine-3,1′-cyclopropane[-5-yloxy[methyl methoxyformate or 1′ -((11S)-7,8-difluoro-6, 11-dihydrodibenzo [b,e]thiepin- 11-yl)- 1′ ,2′ -dihydro-5′-hydroxy-spiro[cyclopropane-1,3′-(3H)pyrido[1,2-b[pyridazine-4′,6′-dione.
6. The amorphous solid dispersion according to claim 5 , wherein the pharmaceutically acceptable polymer is polyvinyl caprolactam-polyvinyl acetate- polyethylene glycol graft copolymer, hydroxypropyl cellulose (HPC), or hydroxypropyl methyl cellulose acetate succinate (HPMCAS).
7. The amorphous solid dispersion according to claim 1 , wherein the weight ratio of the compound of Formula (I) or a pharmaceutically acceptable salt thereof to the pharmaceutically acceptable polymer is in a range between about 1:1 to about 1:3.
8. The amorphous solid dispersion according to claim 1 , wherein the pharmaceutically acceptable polymer is polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, hydroxypropyl cellulose (HPC), or hydroxypropyl methyl cellulose acetate succinate (HPMCAS).
9. The amorphous solid dispersion according to claim 1 , wherein the compound of Formula (I) or a pharmaceutically acceptable salt thereof in the amorphous solid dispersion is 10-60% by weight.
10. The amorphous solid dispersion according to claim 9 , wherein the compound of Formula (I) or a pharmaceutically acceptable salt thereof in the amorphous solid dispersion is 15-50% by weight.
11. The amorphous solid dispersion according to claim 9 , wherein the pharmaceutically acceptable polymer is polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, hydroxypropyl cellulose (HPC), or hydroxypropyl methyl cellulose acetate succinate (HPMCAS).
12. A pharmaceutical composition comprising the amorphous solid dispersion according to claim 1 and one or more pharmaceutically acceptable excipients.
13. The pharmaceutical composition according to claim 12 , wherein the pharmaceutically acceptable polymer is polyvinylpyrrolidone/vinyl acetate copolymer, polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, methacrylic acid and methyl methacrylate copolymer, hydroxypropyl cellulose (HPC), hydroxypropyl methyl cellulose acetate succinate (HPMCAS), hydroxypropyl methyl cellulose phthalate (HPMCP), Polyethylene glycol (PEG), or Kollidon SR.
14. The pharmaceutical composition according to claim 13 , wherein the weight ratio of the compound of Formula (I) or a pharmaceutically acceptable salt thereof to the pharmaceutically acceptable polymer is in a range between about 1:1 to about 1:5.
15. The pharmaceutical composition according to claim 12 , wherein the pharmaceutical composition is in a form of capsule, tablet, powder, pellet, pill, suspension, granule, or inhalant.
16. The pharmaceutical composition according to claim 12 , wherein the pharmaceutically acceptable excipients is selected from binders, glidants, plasticizers, solubilizers, stabilizing agents, antioxidants, diluents, surfactants, disintegrants, lubrients, fillers, wetting agents, sweeteners, colorants, flavors and mixtures thereof.